New hope for lung scarring after transplant: belumosudil trial launches
NCT ID NCT05922761
First seen Feb 27, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase 2 trial tests whether the drug belumosudil can help people who develop bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The study will enroll 45 participants with new or early-stage BOS. Participants will take belumosudil along with standard treatments like steroids and antibiotics to see if lung function improves or stabilizes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Children's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Email: •••••@•••••
Contact
-
Stanford University School of Medicine
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belumosudil (also known as Rezurock), taken as a tablet
What this could lead to
If it works, this could offer a new treatment option for lung damage after stem cell transplant, potentially slowing or improving the condition.
What could go wrong
This is an early-phase, small trial (45 people) with no placebo group, so results may not be definitive. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.